Nilotinib, a tyrosine kinase inhibitor that targets the Abelson tyrosine kinase (c-Abl) signaling pathway, is FDA-approved to treat chronic myeloid leukemia. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.